查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026780

非侵入性產前檢測市場預測至 2034 年—按產品、方法、懷孕週、技術、應用、最終用戶和地區進行全球分析。

Non Invasive Prenatal Testing Market Forecasts to 2034 - Global Analysis By Product, Method, Gestation Period, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球非侵入性產前檢測 (NIPT) 市場規模將達到 58.3 億美元，在預測期內複合年成長率將達到 11.6%，到 ​​2034 年將達到 140.3 億美元。

基於DNA的血液檢測，也稱為非侵入性產前檢測，用於確定發育中胎兒的遺傳疾病風險。一種名為非侵入性產前檢測（NIPT）的篩檢測試在懷孕期間用於識別發育中胎兒的特定遺傳疾病。與羊膜穿刺術或絨毛膜取樣（CVS）等侵入性檢查不同，NIPT是一種非侵入性檢測，只需抽取母親的少量血液樣本即可完成。

根據歐盟統計局的數據，2017年，歐盟約有45%的初產婦屬於平均年齡29.1歲的年齡層。同年，40歲以上女性的初產婦數量約為78,275人。

對準確、先進的篩檢的需求

開發高靈敏度、高精度的先進篩檢方法，用於早期檢測新生兒遺傳異常，一直是許多企業的首要任務。製造商正致力於研發尖端的非侵入性產前診斷技術，並積極尋求策略合作和聯合研究，以擴大市場佔有率。這些因素正在推動市場成長。

諮詢服務有限

雖然非侵入性產前檢測（NIPT）能夠提供有用的信息，但人們並非總是能輕易獲得足夠的諮詢和支持，從而充分理解檢測結果的意義並做出明智的決定。此外，在一些缺乏關於NIPT資料使用和解讀的明確法律規定的地區，其應用可能會引發倫理和法律問題。這些因素正在影響市場擴張。

母親年齡越大，染色體異常的風險越高

高齡產婦更容易出現高血壓、生育能力下降、流產、死產和孕產婦死亡等健康問題。此外，隨著母親年齡的成長，染色體分裂異常可能會增加新生兒患遺傳性疾病的風險。因此，預計市場將受到與母親年齡相關的染色體異常發生率不斷上升的驅動。

測試成本高昂

新興經濟體的人口成長可能因缺乏對遺傳疾病風險的了解而受到阻礙。然而，限制市場擴張的其他挑戰還包括人均醫療費用支出下降和檢測費用報銷機制不足。由於這些檢測費用昂貴，在許多開發中國家難以負擔，這限制了其廣泛應用。

新冠疫情的感染疾病：

在疫情高峰期，產前檢查是難以獲得的常規醫療服務之一。預約取消和轉為線上問診影響了NIPT和其他產前篩檢的正常進行。醫療資源重新分配以應對新冠肺炎病例，可能限制了NIPT檢測的發展，並延長了需要這些服務的人口的等待時間。

在預測期內，超音波市場預計將成為最大的細分市場。

在預測期內，超音波檢查預計將佔據最大的市場佔有率。超音波檢查是目前最常用、最受歡迎的檢查技術，它使用超音波設備。檢查過程中，探頭會將頻率為1-5兆赫茲的聲波脈衝照射到體內。此外，探頭還能接收器從組織表面反射的聲波。

在預測期內，診斷檢查室領域預計將呈現最高的複合年成長率。

在預測期內，診斷檢查室領域預計將呈現最高的複合年成長率。診斷檢查室是進行檢測的場所。檢查室根據患者的需求提供各種檢測服務。由於提供檢測服務和產品的診斷檢查室和中心數量眾多，診斷檢查室類別規模最大。

市佔率最大的地區：

預計北美將在預測期內佔據最大的市場佔有率。在該地區，早產率高、孕產婦死亡率高以及染色體異常發生率不斷上升，預計將推動檢測的普及和需求成長。大量研究表明，意識提升能夠有效促進檢測。此外，較高的診斷率、公眾接受度和意識的提高，以及更新、更先進的檢測技術的出現，都在推動市場擴張。

複合年成長率最高的地區：

預計亞太地區在預測期內將維持最高的複合年成長率。這主要是由於孕婦年齡的成長，導致嬰兒染色體異常的發生率上升，擴大了潛在基本客群。 NGS技術的應用、中國和日本的顯著進步以及醫療基礎設施的不斷完善，預計將推動市場擴張。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 科技
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球無創產前檢測市場：依產品分類

  • 一次性產品
  • 超音波診斷設備
  • 檢測試劑盒和試劑
  • 聚合酵素鏈鎖反應（PCR）裝置
  • 次世代定序系統
  • 微陣列
  • 其他產品

第6章 全球非侵入性產前檢測市場：依檢測方法分類

  • 超音波檢查
  • 生化篩檢試驗
  • 檢測母體血漿中的遊離DNA

第7章 全球非侵入性產前檢測市場：依孕週分類

  • 0-12週
  • 13-24週
  • 25-36週

第8章 全球非侵入性產前檢測市場：依技術分類

  • 次世代定序（NGS）
  • 微陣列
  • 滾動循環放大
  • 其他技術

第9章 全球非侵入性產前檢測市場：依應用領域分類

  • 微缺失症候群
  • 三體症候群
  • 其他用途

第10章 全球無創產前檢測市場：依最終用戶分類

  • 診斷檢查室
  • 醫院
  • 其他最終用戶

第11章 全球無創產前檢測市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第12章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章：公司簡介

  • Centogene NV
  • Natera, Inc.
  • MedGenome Labs Ltd.
  • Eurofins LifeCodexx GmbH
  • F. Hoffmann-La Roche Ltd.
  • Progenity, Inc.
  • Illumina, Inc.
  • Genesis Genetics
  • Qiagen
  • Laboratory Corp. of America Holdings
  • Quest Diagnostics, Inc.
  • PerkinElmer Inc.
  • Your gene Health
  • Perkinelmer, Inc.
Product Code: SMRC24642

According to Stratistics MRC, the Global Non-Invasive Prenatal Testing (NIPT) Market is accounted for $5.83 billion in 2026 and is expected to reach $14.03 billion by 2034 growing at a CAGR of 11.6% during the forecast period. A DNA-based blood test called non-invasive prenatal testing is used to determine the growing foetus's risk of genetic diseases. A sort of screening test called Non-Invasive Prenatal Testing (NIPT) is used to identify specific genetic disorders in the growing fetus during pregnancy. NIPT is a non-invasive treatment that requires a mother's simple blood test, as opposed to invasive procedures like amniocentesis or chorionic villus sampling (CVS).

According to Eurostat, in 2017, around 45% of women in the European Union who gave birth to their first child belonged to the average age group of 29.1 years. Also, in the same year, around 78,275 births of first children were reported in women aged more than 40 years.

Market Dynamics:

Driver:

Need for accurate and sophisticated screening

The development of extremely sophisticated screening methods that are highly sensitive and accurate in the early detection of genetic abnormalities in newborns is a continuing priority for a number of businesses. Manufacturers are placing a lot of emphasis on the creation of cutting-edge noninvasive prenatal diagnostics and forming strategic alliances and collaborations to boost their market share. These are the factors influencing the growth of the market.

Restraint:

Limited availability of counseling

Even while the NIPT offers useful information, people may not always have easy access to enough counseling and assistance to fully comprehend the consequences of the results and make decisions. There may be ethical and legal issues with using NIPT data in some areas due to a lack of defined laws around its usage and interpretation. These are the aspects affecting the market's expansion.

Opportunity:

High risk of chromosomal abnormalities with increasing maternal age

Growing older mothers are more likely to have high blood pressure, limited fertility, miscarriages, stillbirths, and maternal death, among other health problems. Furthermore, the risk of genetic disorders in neonates might increase with maternal age due to improper chromosomal division. Therefore, it is anticipated that the market would be driven by the rising frequency of chromosomal abnormalities along with the aging of mothers.

Threat:

High cost of tests

Growing populations in emerging nations would be hampered by a lack of knowledge about the hazards associated with genetic disorders. However, some other issues that can restrict market expansion include reduced per capita healthcare spending and inadequate test reimbursement rules. The adoption of these tests will be restricted by their high cost, which makes them comparatively unaffordable in many developing nations.

Covid-19 Impact:

Prenatal care was among the regular medical treatments that were difficult to obtain during the pandemic's height. There were some visits that were cancelled or done virtually, which had an impact on the regularity of NIPT and other prenatal tests. In order to handle COVID-19 cases, healthcare resources were reallocated, which could have had an impact on the accessibility of NIPT testing or lengthened wait times for those in need of these services.

The ultrasound detection segment is expected to be the largest during the forecast period

The ultrasound detection segment is expected to be the largest during the forecast period. This is the method that is most favored and used for the ultrasound machine is utilized in this technique. Using a probe, sound pulses with frequency between one and five megahertz are injected into the body during the test. In addition, the probe serves as a receiver for sound waves reflected off tissue surfaces.

The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period. The testing environment where the test is conducted is a diagnostic laboratory. Various testing services are offered by the laboratories based on the needs of the patients. Because there are so many diagnostic labs and centers that offer testing services and goods, the diagnostic laboratories category is the largest.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. The adoption and demand for testing in this region is expected to rise due to the high prevalence of preterm births, high rate of maternal mortality, and increased occurrences of chromosomal abnormalities. Numerous studies provide light on the efficacy of raising awareness of prenatal care. In addition, the market is expanding due to high diagnosis rates, increased public adoption and awareness, and the release of new, more technologically sophisticated tests.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period owing to the rising maternal age, which contributes to the growing incidence of chromosomal aneuploidies in babies, leading to a rise in the potential customer base. The technical integration of NGS techniques, significant advancements in China and Japan, and enhanced healthcare infrastructure are anticipated to propel market expansion.

Key players in the market

Some of the key players in Non-Invasive Prenatal Testing (NIPT) market include Centogene N.V., Natera, Inc., MedGenome Labs Ltd., Eurofins LifeCodexx GmbH, Myriad Women's Health, Inc., F. Hoffmann-La Roche Ltd., Progenity, Inc., Illumina, Inc., Genesis Genetics, Qiagen, Laboratory Corp. of America Holdings, Quest Diagnostics, Inc., PerkinElmer Inc., and Yourgene Health

Key Developments:

In August 2022, Natera Inc. filed a pre-submission to the Food and Drug Administration (FDA) for its panorama non-invasive prenatal test (NIPT) as part of the Q-Sub process. The company filed its pre-submission in June 2022 for fetal chromosomal aneuploidies and 22q11.2 deletion syndrome.

In July 2022, Genetic Technologies Limited acquired EasyDNA as the company expanded the availability on its websites of Carrier Testing and Non-Invasive Prenatal Tests (NIPT) in Europe.

Products Covered:

  • Disposables
  • Ultrasound Devices
  • Assay Kits & Reagents
  • Polymerase Chain Reaction Instruments
  • Next-Generation Sequencing Systems
  • Microarrays
  • Other Products

Methods Covered:

  • Ultrasound Detection
  • Biochemical Screening Tests
  • Cell-Free DNA in Maternal Plasma Tests

Gestation Periods Covered:

  • 0-12 Weeks
  • 13-24 Weeks
  • 25-36 Weeks

Technologies Covered:

  • Next Generation Sequencing (NGS)
  • Microarray
  • Rolling Circular Amplification
  • Other Technologies

Applications Covered:

  • Microdeletion Syndrome
  • Trisomy
  • Other Applications

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Non Invasive Prenatal Testing (NIPT) Market, By Product

  • 5.1 Introduction
  • 5.2 Disposables
  • 5.3 Ultrasound Devices
  • 5.4 Assay Kits & Reagents
  • 5.5 Polymerase Chain Reaction Instruments
  • 5.6 Next-Generation Sequencing Systems
  • 5.7 Microarrays
  • 5.8 Other Products

6 Global Non Invasive Prenatal Testing (NIPT) Market, By Method

  • 6.1 Introduction
  • 6.2 Ultrasound Detection
  • 6.3 Biochemical Screening Tests
  • 6.4 Cell-Free DNA in Maternal Plasma Tests

7 Global Non Invasive Prenatal Testing (NIPT) Market, By Gestation Period

  • 7.1 Introduction
  • 7.2 0-12 Weeks
  • 7.3 13-24 Weeks
  • 7.4 25-36 Weeks

8 Global Non Invasive Prenatal Testing (NIPT) Market, By Technology

  • 8.1 Introduction
  • 8.2 Next Generation Sequencing (NGS)
  • 8.3 Microarray
  • 8.4 Rolling Circular Amplification
  • 8.5 Other Technologies

9 Global Non Invasive Prenatal Testing (NIPT) Market, By Application

  • 9.1 Introduction
  • 9.2 Microdeletion Syndrome
  • 9.3 Trisomy
  • 9.4 Other Applications

10 Global Non Invasive Prenatal Testing (NIPT) Market, By End User

  • 10.1 Introduction
  • 10.2 Diagnostic Laboratories
  • 10.3 Hospitals
  • 10.4 Other End Users

11 Global Non Invasive Prenatal Testing (NIPT) Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Centogene N.V.
  • 13.2 Natera, Inc.
  • 13.3 MedGenome Labs Ltd.
  • 13.4 Eurofins LifeCodexx GmbH
  • 13.5 F. Hoffmann-La Roche Ltd.
  • 13.6 Progenity, Inc.
  • 13.7 Illumina, Inc.
  • 13.8 Genesis Genetics
  • 13.9 Qiagen
  • 13.10 Laboratory Corp. of America Holdings
  • 13.11 Quest Diagnostics, Inc.
  • 13.12 PerkinElmer Inc.
  • 13.13 Your gene Health
  • 13.14 Perkinelmer, Inc.

List of Tables

  • Table 1 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Disposables (2023-2034) ($MN)
  • Table 4 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Ultrasound Devices (2023-2034) ($MN)
  • Table 5 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Assay Kits & Reagents (2023-2034) ($MN)
  • Table 6 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Polymerase Chain Reaction Instruments (2023-2034) ($MN)
  • Table 7 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Next-Generation Sequencing Systems (2023-2034) ($MN)
  • Table 8 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Microarrays (2023-2034) ($MN)
  • Table 9 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 10 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Method (2023-2034) ($MN)
  • Table 11 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Ultrasound Detection (2023-2034) ($MN)
  • Table 12 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Biochemical Screening Tests (2023-2034) ($MN)
  • Table 13 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Cell-Free DNA in Maternal Plasma Tests (2023-2034) ($MN)
  • Table 14 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Gestation Period (2023-2034) ($MN)
  • Table 15 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By 0-12 Weeks (2023-2034) ($MN)
  • Table 16 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By 13-24 Weeks (2023-2034) ($MN)
  • Table 17 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By 25-36 Weeks (2023-2034) ($MN)
  • Table 18 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Technology (2023-2034) ($MN)
  • Table 19 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Next Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 20 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Microarray (2023-2034) ($MN)
  • Table 21 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Rolling Circular Amplification (2023-2034) ($MN)
  • Table 22 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 23 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Application (2023-2034) ($MN)
  • Table 24 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Microdeletion Syndrome (2023-2034) ($MN)
  • Table 25 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Trisomy (2023-2034) ($MN)
  • Table 26 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 27 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By End User (2023-2034) ($MN)
  • Table 28 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 29 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 30 Global Non Invasive Prenatal Testing (NIPT) Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

  • 13.1 Centogene N.V.
  • 13.2 Natera, Inc.
  • 13.3 MedGenome Labs Ltd.
  • 13.4 Eurofins LifeCodeNon Invasive Prenatal Testing (NIPT) GmbH
  • 13.5 F. Hoffmann-La Roche Ltd.
  • 13.6 Progenity, Inc.
  • 13.7 Illumina, Inc.
  • 13.8 Genesis Genetics
  • 13.9 Qiagen
  • 13.10 Laboratory Corp. of America Holdings
  • 13.11 Quest Diagnostics, Inc.
  • 13.12 PerkinElmer Inc.
  • 13.13 Your gene Health
  • 13.14 Perkinelmer, Inc.